Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Lifecare AS ( (DE:LFC0) ) just unveiled an update.
Lifecare ASA has announced the selection of the Pfützner Science & Health Institute (PSHI) in Mainz, Germany, as the second site for its clinical trials of a new CGM implant. This development follows a recent regulatory submission and marks a significant step towards clinical validation and commercialization, with plans for a commercial launch by 2027. The trials at PSHI, led by Dr. Daniela Sachsenheimer and Dr. Julia Jantz, are part of Lifecare’s strategy to advance its clinical roadmap, leveraging a long-standing collaboration with PSHI to ensure successful execution.
More about Lifecare AS
Lifecare ASA is a medical sensor company focused on developing next-generation Continuous Glucose Monitoring (CGM) systems. The company specializes in technology for sensing and monitoring various body analytes, utilizing osmotic pressure as a sensing principle. Their sensor technology is applicable for identifying and monitoring a wide range of analytes and molecules in both humans and pets.
Average Trading Volume: 35,098
Current Market Cap: NOK134.1M
See more data about LFC0 stock on TipRanks’ Stock Analysis page.